AllianceBernstein
SPRO icon

AllianceBernstein’s Spero Therapeutics SPRO Stock Holding History

AllianceBernstein’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,934
Closed -$113K – 3368
2022
Q1 		$113K Hold
12,934
– – ﹤0.01% 3101
2021
Q4 		$207K Buy
12,934
+1,000
+8% +$15.9K ﹤0.01% 3058
2021
Q3 		$220K Sell
11,934
-2,300
-16% -$36.9K ﹤0.01% 3062
2021
Q2 		$199K Buy
14,234
+3,400
+31% +$47.5K ﹤0.01% 3159
2021
Q1 		$159K Hold
10,834
– – ﹤0.01% 3099
2020
Q4 		$210K Sell
10,834
-1,900
-15% -$29.6K ﹤0.01% 2977
2020
Q3 		$142K Hold
12,734
– – ﹤0.01% 3020
2020
Q2 		$172K Buy
+12,734
New +$143K ﹤0.01% 3027

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

AllianceBernstein's SPRO Position: Q2 2022 in Review

AllianceBernstein sold out of Spero Therapeutics (SPRO) in Q2 2022, closing a stake of 12,934 shares — an estimated $113K sold.

AllianceBernstein first reported a position in SPRO in Q2 2020 and held it in 8 quarters. The position peaked at $220K in Q3 2021. 79 funds tracked by Wall St. Rank hold SPRO as of Q2 2022.

  • AllianceBernstein reported no remaining Spero Therapeutics position as of Q2 2022 after selling out during the quarter.
  • AllianceBernstein sold 12,934 Spero Therapeutics shares in Q2 2022, an estimated $113K.
  • AllianceBernstein first reported a position in Spero Therapeutics in Q2 2020 and held it in 8 quarters.
  • AllianceBernstein's Spero Therapeutics position peaked at $220K in Q3 2021.
  • 79 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2022.

Based on AllianceBernstein's 13F filing for Q2 2022, filed 15 Aug 2022.